AC164204

**AC164204** is an Amylin Pharmaceuticals research-stage peptide hybrid, or \"phybrid,\" developed for metabolic disease. It is a single covalently linked peptide molecule comprising the GLP-1 receptor agonist exenatide analog AC3082 and the second-generation amylin analog davalintide, joined through a Gly-Gly-Gly linker. AC164204 acts as an agonist of the glucagon-like peptide 1 receptor and calcitonin receptor-based amylin receptor system. In rodent studies, it improved glucose control and HbA1c and produced greater reductions in food intake and body weight than either exenatide or davalintide monotherapy. Publicly available evidence is limited to preclinical research; no approved product name or clinical development program has been identified. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24167604/))